• Nanion技术: 离子通道研究的智能工具

    Nanion技术: 离子通道研究的智能工具

  • CardioExcyte 96 SOL:用光遗传的手段起搏心肌细胞

    CardioExcyte 96 SOL:用光遗传的手段起搏心肌细胞

  • SURFE²R 96SE: 非标记高通量转运体筛选

    SURFE²R 96SE: 非标记高通量转运体筛选

  • 脂双层记录: Orbit产品系列

    脂双层记录: Orbit产品系列

我们的产品目录

SyncroPatch 384i

SyncroPatch 384i

Patchliner

Patchliner

Port-a-Patch

Port-a-Patch

CardioExcyte 96

CardioExcyte 96

SURFE²R 96SE

SURFE²R 96SE

SURFE²R N1

SURFE²R N1

Orbit 16

Orbit 16

Orbit Mini

Orbit Mini

Vesicle Prep Pro

Vesicle Prep Pro

12.09.2018 | 在线研讨会: CiPA study: Bridging ion channel and myocyte data


180912 event image CiPAII Webinar

Icon CE   CardioExcyte 96, icon pl   Patchliner and   icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i)

日期: 9月12日, 4:00 PM CEST (北京时间10:00 PM)

 获取CiPA肌细胞与离子通道工作组的最新进展:

  • CiPA 肌细胞第二阶段验证研究结果:: cross-site comparison using the CardioExcyte 96
  • 高通量第一阶段研究: an update on progress of the CiPA Ion Channel Work Stream using the SyncroPatch 384PE and Patchliner

演讲人1:
Dr. Sonja Stölzle-Feix
Nanion科学事务主管, CiPA离子通道筛选小组成员
Nanion Technologies GmbH, 德国

演讲主题:
CiPA 肌细胞第二阶段验证研究结果: 使用 CardioExcyte 96进行多位点的横向比较

演讲内容简介:

Since 2005 the S7B and E14 guidances from ICH and FDA have been in place to assess a potential drug candidate's ability to cause long QT syndrome. To refine these guidelines, the FDA proposed the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, where the assessment of drug effects on cardiac repolarization was one subject of investigation. Within the myocyte validation study, effects of pharmaceutical compounds on human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were assessed and this article will focus on the evaluation of the proarrhythmic potential of 23 blinded drugs in four hiPSC-CM cell lines.

Experiments were performed on the CardioExcyte 96 at different sites. A combined readout of contractility (via impedance) and electrophysiology endpoints (field potentials) was performed.Our data demonstrates that hERG blockers such as dofetilide and further high risk categorized compounds prolong the field potential duration. Arrhythmia were detected in both impedance as well as field potential recordings. Intermediate risk compounds induced arrhythmia in almost all cases at the highest dose. In the case of low risk compounds, either a decrease in FPDmax was observed, or not a significant change from pre-addition control values.

With exceptions, hiPSC-CMs are sensitive and exhibit at least 10% delayed or shortened repolarization from pre-addition values and arrhythmia after drug application and thus can provide predictive cardiac electrophysiology data. The baseline electrophysiological parameters vary between iPS cells from different sources, therefore positive and negative control recordings are recommended.


演讲人2: 
Tim Strassmaier
高级应用工程师
Nanion Technologies Inc., 美国

演讲主题:
高通量第一阶段研究: 使用SyncroPatch 384PE与 Patchliner更新CiPA离子通道工作组流程的最新进展。

演讲内容简介:

"The CiPA HTS Ion Channel Working Group finalized its phase I study in 2017. Amongst other external sites, Nanion Technologies in Germany, USA and Japan participated with the Patchliner and the SyncroPatch 384PE in this study. A comparative view of the ion channel targets and a cross-platform and cross-site comparison will be presented. Furthermore, results from the myocyte Work Stream using arrhythmogenic compounds will be compared and confirmed with patch clamp data derived from the HTS Work Stream.“

Please note: The original webinar presentation contained 8 slides with data of an upcoming publication. Due to confidentiality reasons, the relevant slides were cut out of the movie.   

返回总览

 

Nanion运营博客

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok